独立董事 2024 年度述职报告（王先酉） 爱威科技股份有限公司 作为爱威科技股份有限公司（以下简称"公司"）的独立董事，2024 年我 严格根据《中华人民共和国公司法》、《上海证券交易所科创板股票上市规则》、 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》、《上市 公司独立董事管理办法》等法律、法规、规章和规范性文件等的规定和要求，秉 持客观、独立、公正的立场，诚实、勤勉、独立地履行职责，认真审议董事会各 项议案，对公司重大事项发表了独立意见，切实维护公司和公众股东的合法权益， 促进公司规范运作，充分发挥了独立董事及各专门委员会的作用。现将 2024 年 度履职情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 2024 年度，本着勤勉尽责的态度，我积极参加公司召开的董事会、股东大 会和专门委员会，认真审阅会议材料，积极参与各议题的讨论并提出合理建议。 本人王先酉， 1957 年出生，中国国籍，无境外永久居留权,中南大学生理 学博士，生物化学副教授。1980 年至 2002 年先后在湖南省卫生学校、湖南医学 高等专科学校从事医学检验系实验室管理和教学工作，期间 ...

爱威科技股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为规范爱威科技股份有限公司（以下简称"公司"）选聘（含续聘、改聘， 下同）会计师事务所的行为，提高财务信息质量，切实维护股东利益，根据《中华人民 共和国公司法》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易 所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1号— —规范运作》等法律法规、规范性文件等相关规定，并结合公司的实际情况，特制定 本制度。 第二条 公司根据相关法律法规要求选聘会计师事务所对财务会计报告发表审计意 见、出具审计报告，应当遵照本制度履行选聘程序。选聘其他专项审计业务的会计师事 务所，视重要性程度可比照本制度执行。 第三条 公司选聘会计师事务所应当先经董事会审计委员会（以下简称"审计委员 会"）审核同意，再经董事会、股东会审议批准，不得在董事会、股东会审议决定前聘 请会计师事务所开展审计业务。 第四条 公司选聘的会计师事务所，应当符合以下条件： （一）具有独立的主体资格，具备国家行业主管部门和中国证监会规定的开展证券 期货相关业务所需的执业资格； （三）熟悉国家有关财务会计方面的法律、法规、规章 ...

爱威科技股份有限公司 独立董事 2024 年度述职报告（胡型） 作为爱威科技股份有限公司（以下简称"公司"）的独立董事，2024 年我 严格根据《中华人民共和国公司法》、《上海证券交易所科创板股票上市规则》、 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》、《上市 公司独立董事管理办法》等法律、法规、规章和规范性文件等的规定和要求，秉 持客观、独立、公正的立场，诚实、勤勉、独立地履行职责，认真审议董事会各 项议案，对公司重大事项发表了独立意见，切实维护公司和公众股东的合法权益， 促进公司规范运作，充分发挥了独立董事及各专门委员会的作用。现将 2024 年 度履职情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 本人胡型，1979 年出生，中国国籍，无境外永久居留权，管理学学士，中 国注册会计师、税务师、FCAA（英国特许公认会计师资深会员）、CIA（国际注 册内部审计师）。2001 年 7 月至 2003 年 7 月任职于深圳市怡凯发实业有限公 司，任行政助理；2003 年 8 月至 2005 年 10 月任深圳市义达会计师事务所审 计助理、项目经理；2005 ...

Financial Performance - The company's operating revenue for 2024 reached ¥203.32 million, a 1.50% increase compared to ¥200.31 million in 2023[21]. - Net profit attributable to shareholders for 2024 was ¥22.84 million, reflecting a 6.07% increase from ¥21.53 million in 2023[21]. - The net profit after deducting non-recurring gains and losses was ¥15.60 million, up 24.99% from ¥12.48 million in 2023[21]. - The net cash flow from operating activities for 2024 was ¥22.41 million, a slight decrease of 1.40% from ¥22.73 million in 2023[21]. - The total assets at the end of 2024 were ¥561.00 million, a 0.77% increase from ¥556.69 million at the end of 2023[21]. - Basic earnings per share for 2024 were ¥0.34, a 6.25% increase from ¥0.32 in 2023[22]. - The company's net profit increased by 6.07% year-on-year, attributed to cost reduction measures and a higher sales proportion of high-margin reagent and consumable products[23]. - The main business revenue was 198.73 million RMB, a year-on-year increase of 0.95%[93]. - The main business gross margin for reagents was 78.03%, an increase of 2.87 percentage points year-on-year[95]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of RMB 1.00 per 10 shares, totaling RMB 6,727,800 (including tax) based on 67,278,000 shares eligible for distribution[6]. - The total amount for cash dividends and share repurchase reached RMB 16,757,416.35, accounting for 73.36% of the net profit attributable to shareholders for the year[6]. - The cash dividend amount represents 29.45% of the net profit attributable to ordinary shareholders in the consolidated financial statements, which is RMB 22,841,204.65[160]. - The total cash dividend and share repurchase amount over the last three accounting years is RMB 20,327,800, with an average net profit of RMB 20,782,673.49, resulting in a cash dividend ratio of 97.81%[161]. Research and Development - The R&D investment as a percentage of operating revenue decreased to 12.69% in 2024 from 14.48% in 2023, a reduction of 1.79 percentage points[22]. - The total R&D investment for the year is approximately ¥25.79 million, a decrease of 11.05% compared to the previous year, primarily due to reduced R&D personnel and related expenses[62][63]. - The company has invested a total of RMB 89,768,069.81 in research and development over the last three accounting years, accounting for 14.95% of cumulative operating revenue[161]. - The company has established three major technology platforms for automated microscopy, immunology, and clinical testing, enhancing its competitive edge in the market[74]. Market Expansion and Product Development - The company plans to expand into the civilian market in 2025, with a focus on product planning and early promotion[32]. - The company is focusing on international expansion, particularly in Southeast Asia, Europe, and Africa, with a strategy to offer high-cost performance POCT products in emerging markets[52]. - The company is actively developing new products and technologies based on market demand, adhering to a research and development strategy of "mature generation, pre-research generation, and outlook generation"[38]. - The company is focusing on developing new products and technologies in areas such as urine testing, blood testing, and gynecological testing, enhancing its product offerings and market competitiveness[119]. Compliance and Governance - The company has maintained a stable governance structure, with all resolutions passed at the shareholders' meeting being legal and effective, with no rejected proposals[127]. - The company is committed to strict internal management practices, ensuring compliance with public company standards and achieving operational goals through comprehensive management measures[34]. - The company has not reported any significant adverse effects from competition with major shareholders or related parties[127]. - The company has established a commitment to transparency in disclosing shareholding changes during Ding Jianwen's tenure[198]. Risk Management - The company has detailed the major risks it may face in its operations in the report[4]. - The company faced risks related to new product development and registration, which may take several years to obtain necessary approvals, potentially impacting market launch[81]. - The company is subject to strict regulatory requirements in the medical device industry, which could impact operations if compliance is not maintained[83]. Employee and Management - The total number of employees in the parent company and major subsidiaries is 503, with 436 in the parent company and 67 in subsidiaries[150]. - The company has established a performance evaluation system for senior management based on annual performance indicators and management responsibilities[163]. - The company emphasizes continuous employee training, focusing on professional skills and management capabilities to enhance employee competency[153]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, including energy-saving practices and the use of efficient equipment[175]. - The company has made a donation of 0.3 million yuan to the Xinjiang Charity Federation as part of its charitable activities[181]. - The company has a commitment to corporate social responsibility, aiming to create a sustainable environment while enhancing corporate value[169].

Financial Performance - The company's operating revenue for Q1 2025 was ¥53,295,253.92, representing a 13.85% increase compared to ¥46,813,824.02 in the same period last year[4] - Net profit attributable to shareholders was ¥6,321,040.42, up 24.63% from ¥5,071,817.72 year-on-year[4] - The net profit after deducting non-recurring gains and losses increased by 48.77%, reaching ¥5,007,114.43 compared to ¥3,365,606.80 in the previous year[4] - The basic and diluted earnings per share were both ¥0.09, reflecting a 28.57% increase from ¥0.07 in the same period last year[4] - Total operating revenue for Q1 2025 reached CNY 53,295,253.92, an increase of 13.4% compared to CNY 46,813,824.02 in Q1 2024[19] - Net profit for Q1 2025 was CNY 6,321,040.42, representing a 24.6% increase from CNY 5,071,817.72 in Q1 2024[20] - Earnings per share for Q1 2025 were CNY 0.09, compared to CNY 0.07 in Q1 2024[21] - The company reported a total comprehensive income of CNY 6,322,648.15 for Q1 2025, compared to CNY 4,968,248.89 in Q1 2024[21] Cash Flow and Liquidity - The company's cash flow from operating activities turned positive with a net amount of ¥727,164.85, a significant improvement from a negative cash flow of ¥7,769,140.24 in the previous year[4] - Cash flow from operating activities for Q1 2025 was CNY 727,164.85, a significant improvement from a negative cash flow of CNY -7,769,140.24 in Q1 2024[24] - Cash inflow from investment activities in Q1 2025 was CNY 48,790,299.14, compared to CNY 36,589,680.31 in Q1 2024[24] - Cash outflow from investment activities for Q1 2025 totaled CNY 63,976,600.76, down from CNY 88,878,758.00 in Q1 2024[24] - The net increase in cash and cash equivalents was -$14,462,438.09, compared to -$60,051,475.20 in the previous period[25] - The beginning balance of cash and cash equivalents was $53,722,449.10, down from $82,800,209.95[25] - The ending balance of cash and cash equivalents was $39,260,011.01, compared to $22,748,734.75 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥558,947,090.68, a slight decrease of 0.37% from ¥560,997,764.86 at the end of the previous year[5] - The total liabilities decreased to CNY 56,855,378.76 from CNY 65,152,523.33, indicating a reduction of approximately 12.5%[16] - The total non-current assets decreased to CNY 205,517,016.32 from CNY 255,580,492.79, a decline of approximately 19.6%[15] - The company's total equity remained stable at CNY 234,815,828.70 as of both reporting dates[16] Shareholder Information - The total number of common shareholders at the end of the reporting period was 3,605[10] - The company reported a total of 722,000 shares held in the repurchase account, accounting for 1.06% of the total share capital[12] - The company has not identified any significant changes in the participation of major shareholders in margin trading or securities lending activities[12] - There are no known related party transactions among the major shareholders, except for familial relationships disclosed[12] Research and Development - Research and development expenses totaled ¥5,906,072.09, an increase of 11.06% from ¥5,317,736.12, accounting for 11.08% of operating revenue[5] Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[19]

爱威科技股份有限公司董事会审计委员会 对会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求，董事会 审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。对 2024 年度审计机构 天健会计师事务所（特殊普通合伙）（以下简称"天健所"）的工作进行了监督， 现将情况汇报如下： 一、会计师事务所基本情况 （一）会计师事务所基本情况 天健所成立于 2011 年 7 月，注册地址为浙江省杭州市西湖区灵隐街道西溪 路 128 号，首席合伙人为钟建国先生。截至 2024 年 12 月 31 日，天健所合伙人 数量为 241 人，执业注册会计师 2,356 人，其中签署过证券服务业务审计报告的 注册会计师 904 人。天健所 2023 年度经审计业务总收入为人民币 34.83 亿元， 其中审计业务收入 30.99 亿元，证券业务收入 18.40 亿元。2023 年度上市公司（含 A、B 股）审计客户共计 707 家，上市公司审计收费总额人民币 7.2 亿元，这些 上市公司主要行业涉及制造业，信息传输、软件和信息技 ...

证券代码：688067 证券简称：爱威科技 公告编号：2025-010 爱威科技股份有限公司 关于 2024 年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作（2023 年 12 月 修订）》（上证发〔2023〕194 号）的规定，将本公司 2024 年度募集资金存放与 使用情况专项说明如下。 金额单位：人民币万元 项 目 序号 金 额 募集资金净额 A 20,957.98 截至期初累计发生 额 项目投入 B1 7,189.30 购买理财产品净额 B2 9,400.00 利息收入净额 B3 872.38 本期发生额 项目投入 C1 1,486.44 购买理财产品净额 C2 3,200.00 利息收入净额 C3 325.46 截至期末累计发生 额 项目投入 D1=B ...

爱威科技股份有限公司 2025 年度"提质增效重回报"行动方案 为贯彻落实关于开展科创板上市公司"提质增效重回报"专项行动的倡议及 倡议中提出的落实以投资者为本的理念，爱威科技股份有限公司（以下简称 "公 司"）于 2024 年 4 月发布了《2024 年度"提质增效重回报"行动方案》。2024 年内，公司依据方案内容积极开展和落实了相关工作。为切实维护公司全体股东 的根本利益，全方位推动上市公司经营模式的持续优化与升级，公司特制定了 2025 年度"提质增效重回报"行动方案，现将 2024 年度的主要工作成果及 2025 年度方案汇报如下： 一、深度挖掘人工智能潜力，不断拓宽公司产品应用领域 （一）持续挖掘人工智能技术潜力 公司作为显微镜自动化检验先行者，是医学显微镜自动化领域应用最早、产 品覆盖最广的公司之一。公司成立 25 年以来，长期专注于"基于机器视觉技术 的显微镜形态学检验自动化"等人工智能技术的应用研究和相关产品开发。2019 年，经湖南省科学技术厅批准，公司获批组建"湖南省医学显微镜检验人工智能 工程技术研究中心"，该工程技术研究中心是湖南省唯一的省部级医学显微镜检 验人工智能研究中心，主要定 ...

爱威科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开了第 五届董事会第二次会议，审议通过了《关于 2025 年度申请银行授信额度的议案》。 现将相关事项公告如下： 为满足公司生产经营及业务发展需要，公司拟向银行申请不超过人民币 10,000 万元的综合授信额度，授信业务范围包括但不限于信用贷款、应收账款 保理、资产抵押贷款、承兑汇票、贸易融资、保函等。 证券代码：688067 证券简称：爱威科技 公告编号：2025-012 爱威科技股份有限公司 关于 2025 年度申请银行授信额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司本次向银行申请综合授信额度，是为满足公司生产经营和业务发展的需 要，财务风险处于可有效控制的范围内，相关事项不会对公司的正常运作和业务 发展造成不利影响，不会损害公司及股东利益。 特此公告。 爱威科技股份有限公司董事会 2025 年 4 月 29 日 1 以上授信额度不等于公司的实际融资金额，实际融资金额应在授信额度内， 并以银行与公司实际发生的融资金额为准，具 ...

爱威科技股份有限公司董事会审计委员会 2024 年度履职报告 根据《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号—— 规范运作》《上市公司治理准则》《上海证券交易所科创板股票上市规则》等有 关法律法规及《爱威科技股份有限公司公司章程》《爱威科技股份有限公司董事 会审计委员会议事规则》的规定，爱威科技股份有限公司（以下简称"公司"） 董事会审计委员会 2024 年度勤勉尽责,认真履行各项职责和义务，充分发挥公司 审计委员会职能，现将履职情况报告如下： 一、董事会审计委员会基本情况 公司第四届董事会审计委员会由三名委员组成，分别为独立董事阳秋林女士、 独立董事胡型女士、非独立董事王翔先生，其中阳秋林女士任主任委员。审计委 员会各成员具有能够胜任审计委员会工作职责的专业知识和工作经验。 2024 年 11 月 15 日，公司完成了董事会换届选举工作。公司第五届董事会 审计委员会由独立董事万平女士、独立董事张颖先生和非独立董事丁婷女士 3 名成员组成，其中独立董事占比超过二分之一，并由具备专业会计资格的独立董 事万平女士担任审计委员会主任委员。 董事会审计委员会委员任职均符合中国证监会、上海证券交易所的 ...